genetically encoded small-molecule control systems for CAR T cells

These systems provide small-molecule-based control over engineered CAR T cells. The abstract states they can eliminate CAR T cells, switch off their function, directly target antigens, or broaden killing through pro-drug activation.

They require genetically engineered T cells bearing an encoded control system and administration of the relevant small molecule. The abstract does not specify individual construct designs or dosing requirements.

They are presented as approaches to address severe toxicities, limited survival of engineered cells, and therapeutic resistance in CAR T therapy.

The abstract does not claim that these systems fully solve all CAR T limitations or that any one controller addresses every failure mode.

The abstract contrasts multiple controller classes within the small-molecule control space, including protease inhibitors, protein dimerizers, protein degraders, bi-specific adaptors, and conditionally activated chemotherapeutics.